Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK Rapport sur les actions

Capitalisation boursière : US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Paratek Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 1/6

Paratek Pharmaceuticals has a total shareholder equity of $-201.4M and total debt of $258.3M, which brings its debt-to-equity ratio to -128.3%. Its total assets and total liabilities are $145.8M and $347.2M respectively.

Informations clés

-128.3%

Ratio d'endettement

US$258.33m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$42.69m
Fonds propres-US$201.36m
Total du passifUS$347.16m
Total des actifsUS$145.79m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Apr 17
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals: Patience Is Wearing Thin

Aug 24

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Aug 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

Jan 03

The Play On Paratek Pharmaceuticals

Oct 18

Peeking Back In On Paratek Pharmaceuticals

Aug 07

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Jun 16

Paratek shares rise after FDA approves NUZYRA oral only dosing regimen

Jun 01

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Apr 27

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Mar 01
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Feb 01
Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment

Jan 04

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

Dec 01

Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Analyse de la situation financière

Passif à court terme: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Passif à long terme: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Historique et analyse du ratio d'endettement

Niveau d'endettement: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.

Réduire la dette: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: PRTK has sufficient cash runway for more than a year based on its current free cash flow.

Prévisions de trésorerie: Insufficient data to determine if PRTK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Découvrir des entreprises saines